NATOThe NATO is clearly priorising biotech to a defence priority with an annual budget of potentially up to €500m for biotech start-ups starting from 2026. At the opening of the first ever NATO Biotechnology Conference, NATO Secretary General Mark Rutte said: “Between last year and this year, we funded a total of 28 promising biotechnology companies through the Defence Innovation Accelerator for the North Atlantic (DIANA)”. Rutte indicated that DIANA’s budget could grow significantly in the medium term, potentially up to five-fold.
Tag Archive for: biotech
StifelAfter two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.
ASEBIOSpain’s biotech sector drives innovation, economic growth, and scientific excellence. With strong R&D investment, global research impact, and a leading role in gender equality, it’s a key player in health, sustainability, and strategic autonomy. BIOSPAIN 2025 in Barcelona will showcase its potential and connect global biotech leaders.
Johnson & JohnsonThe case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.
Sphene CapitalDespite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
Inflation has rebounded with a vengeance from its pandemic-induced recession lows. The US headline inflation rate surged to levels not seen since Ronald Reagan’s presidency, while the Eurozone’s Harmonised Index of Consumer Price (HICP) rose to the highest level in its entire 30-year lifespan.
From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.
Biotechnology was dramatically rewarded in the financial markets through much of 2020 and the first half of 2021, widely credited for providing the COVID-19 vaccines. This followed four already exceptional years in the financial markets, with the Nasdaq Biotech Index (NBI) hitting its all-time high of 5449.32 on 30 August 2021.
Healthcare has long been considered one of the most reliable defensive sectors – an effective portfolio buffer when equity markets turn volatile. That’s because hospitals, drug makers, medical device firms and other companies across the healthcare sector benefit from steady consumer demand – still true?